CGEM Share Price Performance
US$7.94
-9.61 (-54.76%)
Price US$7.94
Share PriceUS$7.94
CGEM Community Narratives
There are no narratives available yet.
Recent CGEM News & Updates
No updates
Cullinan Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.03
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Cullinan Therapeutics, Inc. Competitors
About CGEM
- Founded
- 2016
- Employees
- 111
- CEO
- WebsiteView website
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. As for the longer term, the market has actually risen by 23% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading